IDiyas

For the Inventor, By the Inventor

Salt Lake City, UT, United States of America

Thomas M Stormann

USPTO Granted Patents = 14

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 270(Granted Patents)


Company Filing History:

goldMedal11 out of 93 
 
Nps Pharmaceuticals, Inc.
 patents
silverMedal4 out of 1,500 
 
Astrazeneca Ab
 patents
where one patent can have more than one assignee

Years Active: 2000-2011

Loading Chart...
14 patents (USPTO):Explore Patents
1. 7964609 - Use of mGluR5 antagonists for the treatment of gerd (2011-06-21),
2. 7585881 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists (2009-09-08),
3. 7456200 - Compounds (2008-11-25),
4. 7262280 - G-protein fusion receptors and constructs encoding same (2007-08-28),
5. 7241863 - Human metabotropic glutamate receptor (2007-07-10),
6. 7112595 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists (2006-09-26),
7. 7053104 - Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases (2006-05-30),
8. 6660753 - Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists (2003-12-09),
9. 6534289 - Nucleic acids encoding mGLuR/CaR chimera (2003-03-18),
10. 6534287 - Human metabotropic glutamate receptor (2003-03-18),
11. 6429207 - Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases (2002-08-06),
12. 6084084 - Human metabotropic glutamate receptor (2000-07-04),
13. 6077675 - Human metabotropic glutamate receptor (2000-06-20),
14. 6051688 - Isolated human metabotropic glutamate receptor Mglur-8 (2000-04-18),

Title: Thomas M Stormann: Innovator in Gastroenterology

Introduction

Thomas M Stormann is a prominent inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of gastroenterology, holding a total of 14 patents. His work focuses on innovative treatments for various gastrointestinal disorders, particularly through the use of metabotropic glutamate receptor 5 antagonists.

Latest Patents

Among his latest patents is the invention related to the use of mGluR5 antagonists for the treatment of gastroesophageal reflux disease (GERD). This invention addresses the inhibition of transient lower esophageal sphincter relaxations, providing a new avenue for treating GERD and regurgitation. Additionally, he has developed new heteropolycyclic compounds that serve as metabotropic glutamate receptor antagonists, which are aimed at preventing and treating mGluR5 receptor-mediated disorders.

Career Highlights

Throughout his career, Thomas has worked with notable companies such as NPS Pharmaceuticals, Inc. and AstraZeneca AB. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative pharmaceutical solutions.

Collaborations

Thomas has collaborated with esteemed colleagues, including Lance G Hammerland and Scott T Moe, further enhancing the impact of his work in the field.

Conclusion

Thomas M Stormann is a distinguished inventor whose work in gastroenterology has led to significant advancements in treatment options for patients. His innovative patents and collaborations reflect his commitment to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…